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The neural circuitry implicated in addictive drug use, which appears to be down-regulated in early 
abstinence, corresponds closely with brain reward pathways. A literature review suggests that 
responses to incentive stimuli and the ability to inhibit reflexive responses, both of which have been 
associated with normal functioning in these pathways, might be weakened during acute abstinence 
from chronic drug use. In an ongoing study, 82 smokers, abstinent overnight before two separate 
testing occasions, have been assessed after administration of nicotine and placebo lozenges (order of 
sessions counterbalanced). Nicotine administration is associated with a significant reduction in 
anhedonia, a near-significant increase in response to financial incentive, enhanced ability to inhibit 
reflexive eye movements, and increased attentional bias to words with appetitive significance. Fifty-
nine participants then initiated a quit attempt and 19 reported relapsing within 7 days. Comparing their 
performance in the two prequit lozenge assessment sessions, relapsers showed a stronger effect of 
nicotine on enhancing their ability to inhibit reflexive eye movements and a near-significant trend 
towards greater nicotine-induced increases in attentional bias toward appetitive words. 
 





An intricate system of biological engineering connects the momentary action of ingesting a drug with 
the ensuing complex of cognitive, affective, and behavioural reactions. The essence of addiction lies in 
the behavioural reaction, shown by some individuals, of continuously repeating the original act of drug 
ingestion despite many apparently maladaptive physical and psychosocial consequences. These 
behavioural reactions, however, are likely to be in large part mediated by the impact of the drug both 
on various parameters of the physical functioning of the brain and on associated subjective experiences. 
These effects are liable to vary as a function of extent and frequency of drug exposure. For instance, a 
particular drug administered acutely may have a transient and subjectively positive effect on the 
functioning of brain structures and pathways involved in anxiety. Chronic use, however, may be 
associated with the evolution of longer term alterations to brain structure or function, which mean that 
administration of the drug now produces a rather different constellation of physical effects that 
manifest in a different set of subjective experiences. 
 
The complexity of potential drug effects is further exacerbated by preexisting differences between 
individuals in parameters of their brain function and personality, either constitutional or acquired, and 
by situational factors (e.g., current exposure to stressors) that themselves directly affect brain activity 
and mood as well as providing a psychological context for the physiological and subjective impact of 
drugs. Despite, or perhaps because of, this complexity, the coupling of increasingly sophisticated 
technologies for mapping brain–behaviour relationships with well-articulated neuropsychological 
theories of cognitive and affective information processing has led to the emergence over the past two 
decades of some compelling neuroscientific models of addiction. However, although empirical 
validation of key tenets of these models is gradually accumulating, there is as yet a lack of data 
concerning the extent of their clinical utility in allowing ‘‘at-risk’’ individuals to be identified or 
effective treatments to be derived and then targeted appropriately. 
 
The purpose of the present paper is first to consider some of the neuropsychological and clinical 
implications of evidence implicating the mesocorticolimbic ‘‘reward’’ pathways in the use of addictive 
drugs, specifically in the use of nicotine. We also present some preliminary data from an ongoing study 
of smoking cessation designed to test theoretically derived hypotheses concerning the effect of acute 
nicotine administration and abstinence on cognitive and affective functions in chronic smokers, and 
also to explore whether individual differences in the magnitude of these effects predicts success/failure 
in maintaining abstinence over a 3 month period. 
 
1.1. Addiction and brain reward pathways 
 
There is now substantial preclinical and clinical evidence that repeated use of centrally acting 
‘‘recreational’’ substances (including nicotine, alcohol, cannabis, psychomotor stimulants, and opiates) 
is associated with abnormal functioning in brain pathways that underlie both reward motivation and the 
‘‘executive’’ cognitive processes involved in strategy formation and inhibitory response control. 
 
The neural circuitry implicated in the above functions—the mesocorticolimbic brain system—
comprises dopaminergic projections from the ventral tegmental area (VTA) to structures including the 
nucleus accumbens (NAcc), amygdala, anterior cingulate, and prefrontal cortex (PFC). Activation of 
these structures has been found to be associated with appetitive behaviours directed at obtaining a wide 
range of reinforcers including brain electrostimulation, food, and sex (e.g., Wise, 1998), and 
collectively they are consequently referred to as the ‘‘reward system.’’ A substantial empirical 
literature shows that dopamine release is triggered both by consumption of a drug and, through 
classical conditioning, by exposure to stimuli, which have formerly been predictive of drug 
consumption. Conditioning studies have confirmed that formerly neutral stimuli repeatedly paired with 
either food (e.g., Schultz, Apicella, & Ljungberg, 1993) or drugs (e.g., Di Ciano, Blaha, & Phillips, 
1995) can indeed come to elicit conditioned release of DA in the NAcc. In their ‘‘incentive 
sensitisation’’ model of addiction, Robinson and Berridge (1993, 2000) have argued that repeated drug 
use sensitises (enhances the reactivity of) this system so that stimuli with motivational significance 
(particularly drug related) elicit stronger reactions; subjectively, they ‘‘grab the attention’’ and acquire 
greater incentive salience. This leads to heightened appetitive urges or ‘‘cravings’’ that in turn 
contribute, along with other more explicit cognitive processes, to the maintenance of a compulsive 
pattern of drug seeking and ingestion (Berridge & Robinson, 2003). Other researchers have similarly 
postulated that increases in dopamine activity are associated with heightened sensitivity and/or 
behavioural responsiveness to stimuli with motivational significance, including those with aversive as 
well as appetitive connotations (e.g., Salamone, 1994). 
 
Consistent with this model, there is evidence for ‘‘cross-priming,’’ in which users of one addictive 
substance show elevated craving for or consumption of that drug if they have previously been 
administered a dose of another dopamine agonist (see review by Self, 1998). For example, Reid, 
Mickalian, Delucchi, Hall, and Berger (1998) found in a double-blind, placebo-controlled study that the 
increases in craving reported by abstaining cocaine addicts during exposure to cocaine-related cues 
were strongly enhanced by an acute dose of nicotine administered via a transdermal patch. Additional 
support accrues from numerous neuroimaging studies showing drug craving to be accompanied by 
activation of brain areas traversed by mesocorticolimbic dopaminergic pathways (e.g., Childress et al., 
1999; Grant et al., 1996; Sell et al., 1999; Volkow, Wang, et al., 1999). 
 
1.2. Abnormalities of brain dopamine pathways during abstinence 
 
Chronic use of addictive drugs has been associated with abnormalities in dopaminergic pathways. For 
example, Kuhar and Pilotte (1996) reported long-lasting decreases in DA transporter levels in the NAcc 
in animals after cocaine withdrawal; similarly, in humans Volkow, Fowler, and Wang (1999) 
concluded from a series of PET studies that addictive cocaine users have abnormally low levels of 
dopamine D2 receptors and that this in turn is associated with decreased metabolism in the cingulate 
gyrus and orbitofrontal cortex. Confirming this abnormality, Little, Patel, Clark, and Butts (1996) 
found depleted dopamine levels at postmortem in the frontal cortex of cocaine users by comparison 
with those of matched noncocaine users. Altmann et al. (1996) concluded from an extensive literature 
review that ‘‘withdrawal from various drugs of abuse is associated with a reduction in dopamine 
transmission in the ventral striatum, an effect that is opposite to the common property of drugs of abuse 
to stimulate dopamine transmission. . .’’ (p. 316). 
1.3. Brain reward pathways and cognitive functioning 
 
In addition to providing some explanation of subjective and behavioural phenomena in drug addiction, 
such as the urges or cravings that substance users experience when exposed to drug-related cues and 
the difficulty in maintaining abstinence after a single lapse, this neurobiological model has implications 
for cognitive functioning. The mesocortical projections activated by dopamine release in the VTA 
terminate widely throughout the PFC: Differing regions within the PFC are critical for a variety of 
high-level ‘‘executive’’ functions essential to the inhibition of automatic reflexive responses and the 
generation, execution, and monitoring of effective problem solving or strategically controlled 
behaviours (e.g., Norman & Shallice, 1983), though, as Aron, Robbins, and Poldrack (2004) note, there 
have been conflicting findings in relation to neuroanatomical correspondences between specific 
executive functions and subregions of PFC. 
 
Jentsch and Taylor (1999) have reviewed a substantial body of preclinical and clinical studies 
suggesting that chronic use of addictive substances is associated with impairments of impulse control 
(or response inhibition), an aspect of behaviour that elsewhere has been linked with activity in the 
orbitofrontal cortex (e.g., Arana et al., 2003). Jentsch and Taylor make a strong case that such 
impairments may play a critical role in vulnerability to relapse, in that they will reduce the addict’s 
ability to resist the strong habitual drug-using responses elicited by drug-related cues. Consistent with 
this, substance users have been found to show impairments of automatic response inhibition (e.g., 
Kaufman, Ross, Stein, & Garavan 2003), as well as elevated impulsiveness and risk taking on 
behavioural tasks (e.g., Lejuez et al., 2002). Relatedly, Bechara et al. (2001) found substance users’ 
decision making to be abnormally strongly influenced by short-term over long-term outcomes (a 
pattern also shown by patients with prefrontal brain lesions and associated with trait impulsiveness; 
Hinson, Jameson, & Whitney, 2003). Of particular interest here, Spinella (2002) reported that in 
smokers, the degree of impairment on such tasks correlated positively with the amount they reported 
smoking. 
 
Goldstein and Volkow (2002) have explicitly linked the motivational and cognitive disruptions 
theoretically likely to arise from the effects of addictive drugs on reward pathways within a framework 
that they term Impaired Response Inhibition and Salience Attribution (I-RISA), and they cite extensive 
neuroimaging data supporting the associations between addiction, abnormalities of brain structure and 
function, and disturbances of cognitive and behavioural responding. 
 
1.4. Smoking and brain reward pathways 
 
When administered acutely, nicotine directly stimulates dopamine release within the mesocorticolimbic 
circuitry: It attaches to acetylcholine receptors on neurons in the VTA that project to the NAcc and, by 
so doing, increases release of dopamine in the shell of NAcc (Gamberino & Gold, 1999). Confirming 
the correlation between activation of these pathways and the subjective effects of smoking in an fMRI 
study, Stein et al. (1998) found that injections of nicotine in smokers induced parallel increases in 
reports of various drug-positive sensations and activity in the NAcc, amygdala, limbic thalamus, 
anterior cingulate, and dorsolateral, orbital, and medial frontal regions of the frontal lobes. 
 
Complementing these acute effects, long-term nicotine use—like chronic use of other addictive 
drugs—appears to be associated with neuroadaptations in dopaminergic pathways. For example, Fung 
et al, (1996) report that rats addicted to and then withdrawn from nicotine for 24 h showed reduced 
levels of DA in the striatum and NAcc and decreased numbers of DA receptors in the NAcc. By 
contrast, DA levels in the striatum were increased 5 days after nicotine administration, returning to 
baseline levels after 14 days (Fung & Lau, 1988). Whereas long-term administration has been found 
not to lead to any alteration in the degree to which nicotine ingestion triggers the release of DA in the 
NAcc (Gamberino & Gold, 1999), Epping-Jordan, Watkins, Koob, and Markou (1998) found that 
across 4 days of nicotine withdrawal rats showed significantly increased thresholds for intracranial 
stimulation; thus, there do appear to be changes in functional characteristics of the brain reward 
circuitry during abstinence. Paralleling these preclinical findings, in humans positron emission 
tomography (PET) has shown the brains of current smokers, but not ex-smokers, to be characterised by 
abnormally low levels of monoamine oxidase B, an enzyme that metabolises DA (Fowler et al., 1998). 
In smokers who had abstained for several hours, Geracioti, Scott, West et al., (1999) found CSF levels 
of the DA metabolite homovanillic acid to be half that of a group of nonsmokers, whereas in a PET 
study by Dagher et al. (2001), smokers showed reduced dopamine D1 receptor binding in the ventral 
striatum compared with nonsmokers. 
 
It remains unclear from cross-sectional studies such as these whether the observed abnormalities 
antedated or were a consequence of chronic smoking: Although the normality of some aspects of 
functioning in ex-smokers might suggest that the impairments seen in current smokers are reversible 
sequelae of nicotine use, it is also possible that successful quitters are atypical of the broader 
population of smokers. Prospective longitudinal studies tracking smokers over weeks or months of 
abstinence are needed to determine whether abnormalities do in fact recover over time, and to 
differentiate between transient withdrawal effects and longer term down-regulation. 
 
Taken together, these data suggest that although regular smokers continue to experience dopamine-
boosting effects of nicotine, their endogenous dopamine systems are likely to be suppressed or down-
regulated in some manner that will be revealed during a period of acute abstinence. Indeed, Wise and 
Munn (1995) have suggested that acute dopamine depletion during withdrawal might underlie the 
characteristic subjective reports of anhedonia and dysphoria. A recent study by Gilbert et al. (1999) 
found that by comparison with current smokers, abstaining smokers showed abnormalities of right–left 
EEG asymmetry that persisted without substantial change across 31 days of abstinence and that 
correlated with trait depression. Elsewhere, EEG asymmetry has been considered a physiological 
marker of approach motivation and has been shown to increase during exposure to smoking-related 
cues (Zinser, Fiore, Davidson, & Baker, 1999). Although these findings do not directly demonstrate 
dopaminergic alterations, they do suggest that abstinence may be associated with prolonged 
physiological abnormalities. 
 
1.5. Nicotine: effects of acute abstinence and smoking 
 
If dopaminergic brain reward mechanisms in chronic smokers are indeed dysfunctional during acute 
abstinence, then from the foregoing neuropsychological analysis it follows that acutely abstinent 
smokers should show disturbances in their responses to incentives and in their ability to inhibit 
prepotent or reflexive responses. Although little research has directly examined these cognitive and 
behavioural processes as a function of nicotine use and abstinence, Bickel, Odum, and Madden (1999) 
and Mitchell (1999) both reported that current smokers were more likely than nonsmokers or ex-
smokers to respond preferentially for smaller, immediate monetary rewards over delayed but larger 
rewards. This pattern of responding, often characterised as ‘‘impulsive,’’ may be construed as 
reflecting a heightened salience of the immediately available reward and/or difficulty in inhibiting an 
automatic tendency to respond for immediate reward. 
 
Our group has now conducted a number of studies with smokers to investigate responses to 
motivationally salient (but non-drug-related) cues and inhibitory response control under conditions of 
acute abstinence and immediately after smoking. To measure individual variation in response to 
incentive, we used the Card Arranging Reward Responsivity Objective Test (CARROT; Powell, Al-
Adawi, Morgan, & Greenwood, 1996). Here, the participant is presented with a stack of cards, each 
having five digits printed on it; one (and only one) of the digits is either a 1, 2, or 3, and the cards have 
to be sorted into three piles corresponding to these digits. Four trials are given (T1, T2, T3, and T4). In 
T1, the participant is told to sort a stack of 60 cards as quickly as possible. The time taken to do so is 
recorded, and is used as the individually determined time given for subsequent trials. T1 thus serves 
both to familiarise the participant with the task and, of particular relevance in the case of neurological 
or psychiatric groups, to ensure that subsequent trial times are adjusted to control for any sensory, 
motor, or cognitive deficits. In T2 and T4, the participant is required simply to sort the cards as quickly 
as possible. The mean rate of card sorting in these two trials represents ‘‘nonrewarded’’ rate 
(NRRATE). T3 differs only in that the participant is told that for every five cards sorted, he will 
receive a reward of 10 pence. During the trial, coins are placed on the table in full view after every fifth 
card. Rate of card sorting in this trial represents ‘‘rewarded’’ rate (REWRATE). ‘‘Reward 
responsivity’’ (REWRESP) is then computed as (REWRATE — NRRATE). Pilot work in healthy 
volunteers showed a highly significant enhancement in sorting rate in the rewarded condition (P < .001; 
Pickering, Corr, Powell et al., 1997), whereas neurological patients with severely impaired motivation 
in daily life showed a virtual lack of response to financial incentive (Al-Adawi, Powell, & Greenwood, 
1998). In a case series of 11 such patients, both CARROT performance and an ecological measure of 
motivation (participation in therapeutic activities) normalised after treatment with a dopamine agonist, 
bromocriptine (Powell et al., 1996). 
 
In relation to nicotine, a naturalistic study by Al-Adawi and Powell (1997) involved assessing a sample 
of smokers firstly during a period of voluntary acute abstinence observed for religious reasons 
(Ramadan) and then immediately after they had smoked a cigarette at the end of this abstinence period. 
Smokers showed significantly lower reward responsivity on the CARROT when they were tested after 
a few hours abstinence than when they were retested after smoking, and also showed significantly 
lower reward responsivity than a comparable group of nonsmokers. Baseline psychomotor speed did 
not differ between conditions or groups. 
 
We replicated and extended the above findings in an experimental study with 26 smokers (Powell, 
Dawkins, & Davies, 2002) where testing order (abstinent vs. after smoking) was counterbalanced. A 
comparison group of nonsmokers was assessed at the same time points. In addition to the CARROT, 
response inhibition was assessed using an oculomotor task that required participants to inhibit reflexive 
eye movements (‘‘prosaccades’’) towards a peripheral stimulus and instead to make ‘‘antisaccades’’ 
(movements in the opposite direction from the stimulus). This task has previously been linked with 
activation of both PFC and anterior cingulate (e.g., Everling & Fischer, 1998; Gooding, Iacono, & 
Grove, 1997) and, functionally, with executive cognitive processes (e.g., Findlay & Walker, 1999). 
 
The results of this study were striking. Firstly, reward responsivity was significantly lower in the 
abstinent than the just-smoked condition, regardless of order of testing; performance in the just-smoked 
condition did not differ from that of nonsmokers. This effect remained significant, to almost the same 
degree, when the influence of subjective withdrawal symptoms was covaried out. By contrast, 
psychomotor speed in the baseline trial of the CARROT did not differ as a function of abstinence. 
Secondly, the error rate for antisaccades, but not reflexive saccades, was likewise significantly higher 
during abstinence than just after smoking and than in nonsmokers. Again, severity of withdrawal 
symptoms did not explain this pattern. Impairment on the antisaccadic task during abstinence 
(computed by subtracting abstinence score from postsmoking score) was strongly correlated with 
number of cigarettes smoked per day (r=.53, P < .01), suggesting that more severely addicted 
individuals experience greater smoking-induced enhancements of their ability to inhibit reflexive 
responses than do lighter smokers. 
 
We also included a measure of response to ecological incentives in daily life: the Snaith– Hamilton 
Pleasure Scale (SHAPS; Snaith et al., 1995). This asked participants to rate their enjoyment of various 
normal enjoyable activities over the last few days. Here a significant negative effect of abstinence was 
again observed, by comparison both with the smoking condition and with nonsmokers. 
 
A third study (Powell, Tait, & Lessiter, 2002) tested a different prediction derived from the incentive 
motivational model concerning attentional bias. Salamone (1994) and Robinson and Berridge (2000), 
among others, have argued that dopamine release during exposure to cues with motivational 
significance is associated with an increased tendency to notice or attend to them. If there is indeed such 
a causal link, we hypothesised that individuals with high functional dopamine activity—including 
smokers who have just had a cigarette—should find it harder to ignore motivationally relevant 
information than individuals with relatively low functional dopamine activity; this latter group should 
include acutely abstinent smokers. We assessed this by using a modified Stroop task in which 
participants were instructed to name the ink colours in which an array of different words were printed. 
In one version of the task the words were affectively neutral (e.g., ‘‘pavement,’’ ‘‘emulsion,’’ 
‘‘cadet’’); in another version they were appetitively toned but unconnected with nicotine or other drug 
use (e.g., ‘‘affection,’’ ‘‘caress,’’ ‘‘passion’’); and in a third they were aversive or threat related (e.g., 
‘‘coffin,’’ ‘‘blunder’’, ‘‘ambulance’’). The different word categories were matched for word frequency 
and word length. Twenty-one smokers were assessed on all three versions, once after several hours 
abstinence and once immediately after smoking; orders of condition and word category were 
counterbalanced. Ten nonsmokers, equivalent to the smoking group in sex ratio, age, and educational 
level, were assessed once only. The dependent variable of primary interest was the time it took to 
colour name the words of each type. As predicted, both appetitive and aversive words slowed colour 
naming in recent smokers and nonsmokers, whereas abstinent smokers showed no greater effect of 
these word types than of neutral words. This did not reflect any overall psychomotor slowing. These 
data appear to demonstrate that attentional orienting is affected in a very specific way by nicotine 
consumption and/or abstinence. The results are consistent with a dopaminergic model of incentive 
motivation, but are crucially different from the results of other assessment tools we have used in 
showing nicotine-related effects at an earlier stage in the processes linking perception of environmental 
stimuli with behavioural responses. 
 
One significant limitation of all of the above studies is that nicotine was administered via cigarette 
smoking. Although nicotine is believed to be the primary psychoactive ingredient in tobacco, it is by no 
means the only one and it is therefore possible that the observed effects are not directly attributable to 
nicotine. Perhaps more problematically, it was not possible to find a suitable placebo control: Smokers 
are well able to detect the difference between no/low nicotine and high nicotine cigarettes. 
Consequently the studies used nonblinded designs and left open the possibility that beliefs and 
expectancies on the part of either the participants or the researchers might have influenced task 
performances. A study currently in progress has therefore elected to administer nicotine in lozenge 
form, with an indistinguishable placebo provided by the pharmaceutical manufacturer. This has 
enabled us to achieve double blindness and to deliver nicotine in a pure form. 
 
In addition to attempting a replication of the previously observed findings using the more rigorous 
methodology, the study aimed to address two additional questions of theoretical and clinical 
significance. 
 
1.5.1. Do impairments observed during acute abstinence predict relapse? 
 
There are at least two reasons for hypothesising that this might be the case. Firstly, if incentive 
motivation is lowered, the abstaining smoker’s resultant state of anhedonia or inertia means that the 
smoker may fail to engage in or achieve the same degree of enjoyment as before from normally 
pleasurable activities. Thus, not only has the smoker lost the pleasure normally afforded directly by 
smoking, but exposure to, or enjoyment of, alternative sources of pleasure may be reduced. The ‘‘quick 
fix’’ provided through exogenous stimulation of reward pathways by smoking may therefore be more 
salient. Secondly, and in parallel, the more that response inhibition is impaired during abstinence, the 
greater should be the difficulty in resisting reflex response to smoke a cigarette when one is available 
or when the response is cued by a particular context. 
 
1.5.2. Do impairments observed during acute abstinence show recovery over protracted 
abstinence? 
 
The abnormalities seen during acute abstinence could either (i) be temporary deficits resulting from 
reversible neuroadaptations; (ii) be permanent deficits resulting from irreversible neural changes; or 
(iii) have antedated the onset of smoking. If (i) is the case, then functioning should gradually normalise 
over a period of abstinence. 
 
Few if any studies to date have tracked any aspects of cognitive functioning across weeks or months of 
abstinence, and the evidence in relation to physiological functioning is complex. For example, most 
mood and physical withdrawal symptoms self-reported by abstaining smokers ameliorate over a period 
of up to 4 weeks; increases in appetite are the exception to this profile of recovery (e.g., West, Hajek, 
& Belcher, 1987). However, the changes induced by nicotine dependence go beyond those that are 
manifest as withdrawal symptoms. This is clearly illustrated by a recent study (Carboni, Bortone, Ciua, 
& Di Chiara, 2000) in which rats were experimentally addicted to nicotine. Nicotine dependence was 
shown to be associated with alterations in dopaminergic function in the NAcc, but whereas 
administration of the opiate antagonist naloxone triggered physical withdrawal symptoms it had no 
effect on central DA transmission. The authors concluded that ‘‘the physical signs of nicotine 
dependence [may be] dissociated from the motivational state of withdrawal (anhedonia) and from the 






The present data come from an ongoing prospective longitudinal investigation addressing the above 
questions. We are aiming to recruit a total of 200 smokers who are willing to make an attempt to quit, 
and of these 75% will be randomly allocated to a quit group and the remaining 25% to a nonquit 
(‘‘smoke’’) group. 
 
Before randomisation between quit and ‘‘smoke’’ groups, all participants are evaluated on a range of 
cognitive and behavioural tasks using a mixed within- and between-subjects design. They are assessed 
on two separate mornings, after overnight abstinence on both occasions, under two experimental 
conditions that are administered in counterbalanced order. On both sessions they are given a lozenge to 
start sucking approximately 25 min before the commencement of testing; in one session this contains 4 
mg nicotine, and in the other it is a placebo constructed by the pharmaceutical company (Glaxo Smith 
Kline) to look and taste similar. This lozenge dissolves over the course of the next 45 min or so, and an 
hour after administration of the first lozenge, participants are given another identical one to suck. This 
procedure is designed to achieve more or less stable levels of blood nicotine throughout the testing 
procedures. Both the participant and the assessor are blind to experimental condition. 
 
Participants are notified of their group allocation after completion of the second session, and ‘‘quit’’ 
participants commence their abstinence attempt immediately. They are not permitted to use nicotine 
replacement therapy of any form. Follow-up assessments are conducted with participants in both 
groups 7, 30, and 90 days after randomisation, the randomised design controlling for the effects of 
repeated assessment. 
 
Based on typical clinical relapse rates, it is anticipated that approximately 75 of the quit group will 
remain abstinent at 7 days, 45 at 30 days, and 20–30 at 90 days. Relapse is defined operationally as 
self-reported smoking in any amount, or use of any nicotine product, or a salivary cotinine 
concentration of greater than 20 ng/ml. Relapsers are asked to participate in the next scheduled 
assessment after their relapse, where they are assessed for a final time on the experimental measures 
and are interviewed concerning the nature and extent of the relapse; thereafter they do not take part in 
subsequent assessments. 
 
Because the recruitment, assessment and data entry are all ongoing, the present preliminary report is 
restricted to a comparison of the effects of nicotine and placebo lozenges on four measures of incentive 
motivation and response inhibition, and to correlations between these variables and duration of 
abstinence up until the first (7 day) assessment. We have not yet entered sufficient data to address the 
question of possible recovery in functioning over increasing duration of abstinence, nor do we report 
here the full range of measures used in the full study, where additional cognitive, behavioural, 




Participants are recruited through advertisement in local newspapers and notices displayed in 
community facilities such as colleges, GP surgeries, and libraries. All participants are aged 18–65 
years, have smoked a minimum of 10 cigarettes a day for 6 months, and must be willing to make an 
attempt to quit. Exclusion criteria include current treatment for depression or any other psychiatric 




Participants in the quit group are given an information booklet, access to a telephone ‘‘helpline’’ and 
brief individualised advice and support at the end of each assessment session designed to maximise 
abstinence rates and retention to the study. They are required to refrain from using any nicotine-
replacement therapy (NRT) or other psychotropic medication (e.g., bupropion) during the quit attempt. 
Salivary cotinine levels are measured at each assessment to characterise participants’ level of nicotine 
intake and to verify self-reported abstinence.  
 
All participants in both groups are paid £20 for attending each of the six assessments they attend, but, 
to minimise attrition, do not receive their accumulated ‘‘earnings’’ (other than any travel costs) until 






2.4. Baseline assessments  
 
In addition to basic demographic information (age, gender, ethnicity, socioeconomic status, and 
educational level), various indices of extent of smoking and dependence are gathered including the 
following: 
 
 The Fagerström Test for Nicotine Dependence (FTND) (Heatherton, Kozlowski, Frecker,& 
Fagerström 1991): on this six item self-report scale scores range from 0 (low dependence) 
to 10 (high dependence). 
 
 Expired carbon monoxide, to index recent smoking, is recorded via a breath CO monitor. 
         Nonsmokers and smokers who have abstained overnight typically have levels < 11 ppm. 
 
 
2.5. Cognitive and motivational assessments 
 
2.5.1. Incentive motivation 
 
2.5.1.1. Card Arranging Reward Responsivity Objective Test. This yields an index of the extent to 
which participants enhance performance on a simple psychomotor task when offered a financial 
incentive. Briefly, participants are given a stack of cards to sort into three piles based simply on the 
presence of one of three numbers on the card. After a familiarisation trial their rates of sorting in three 
subsequent trials are recorded: In the first and third of these, participants are requested to sort as 
quickly as they can, but are not given any financial incentive, whereas in the second trial they are 
offered an incentive of 10 pence for every five cards they sort within an individually determined time 
limit (the number of seconds they took to sort 60 cards during the familiarisation trial). The variable of 
principal interest is ‘‘reward responsivity’’—the increment in rate of sorting seen in the rewarded trial 
compared with the average of the two nonrewarded trials. 
 
2.5.1.2. Modified Stroop test of attentional bias. Participants are required to name the colours of the ink 
in which an array of 88 words (eight repetitions of each of 11 different words, in random order) are 
printed on a handheld sheet. There are four trials, each presenting words of a different semantic type 
(neutral, appetitive, threat, smoking related), matched for word frequency and length, given in 
counterbalanced order across participants so that each word type occurs equally often in each 
sequential position. Number of errors and total naming time are recorded for each word type. 
 
2.5.1.3. Anhedonia. The SHAPS (Snaith et al., 1995) is a 14 item self-report scale designed to assess 
state-dependent hedonic tone in both the general population and psychiatric patients. Subjects are asked 
whether each of 14 normally pleasurable events or activities would give them pleasure; here, each item 
is scored 1 (strongly agree) to 3 (strongly disagree). Thus, the score range is from 0 to 42, with a higher 
score indicating greater anhedonia.  
 
2.5.2. Response inhibition/impulsiveness 
 
2.5.2.1. Eye movement task. Participants are instructed either to move their gaze towards a visually 
presented peripheral stimulus (the ‘‘prosaccadic’’ reflexive response) or to inhibit this response and 
look instead in the opposite direction (‘‘antisaccadic’’ response). 
 
The procedure used that employed by Fukushima, Fukushima, Miyasaka, and Yamashita (1994) and 
Clementz, McDowell, and Zissok (1994). Participants are tested in a quiet, darkened room where they 
are seated in front of a 35-cm computer monitor and fitted with eye-tracking headgear. A chin rest, 
positioned 25 cm from the screen, minimises head movements. The equipment is calibrated for each 
participant before each of the two tasks by asking them to look at a white dot subtending a visual angle 
of < 0.25 against a dark background at three positions (central fixation, + 24j and —24j) for 5 s each. 
Horizontal eye movements are measured for the right eye only by using an infrared reflection technique 
(IRIS IR 6500 by Skalar Medical) with a sampling rate of 120 Hz. Incoming eye-movement recordings 
are digitised using a Brain Boxes 12-bit analogue to digital conversion card. 
 
In the experimental task, a central fixation target is presented for a period varying randomly between 2 
and 4 s. Two hundred milliseconds after extinction of the fixation point, one of six peripheral targets is 
illuminated for 500 ms. The central fixation point is then reilluminated. Peripheral targets vary in both 
direction (left or right of the central fixation point) and amplitude (i.e., 8j, 12j, or 24j) and are presented 
in a randomised order. Sixty peripheral stimuli are presented, 10 in each of the six possible positions. 
 
This procedure is conducted firstly with prosaccades, when participants are instructed to look at the 
peripheral target as quickly and accurately as possible, and then, after a 5-min break, with antisaccades, 
when they are told instead to look in the opposite direction as quickly as possible and at approximately 
equal distance from the fixation point. Within each condition, responses are classified as incorrect if the 
initial movement is in the wrong direction regardless of whether or not it is subsequently corrected. The 
dependent variables analysed here are the number of correct responses (across all stimulus locations; 




At this stage in the study,1 we have entered data on 109 participants who have attended both baseline 
lozenge (nicotine and placebo) sessions; of these, 73 allocated to the quit group have data for duration 
of abstinence up to 7 days. Therefore, in the analyses described below, whereas comparisons of 
cognitive test performance between nicotine and placebo conditions are based on the full sample of 109 
participants, the predictive relationship of these measures to abstinence duration across the first week is 
limited to the smaller sample. 
 
3.1. Participant characteristics 
 
The participants comprise 50 men and 59 women, with a mean age of 31.0 years (S.D. = 11.9, range 
19–63). Average duration of smoking is 15.2 years (S.D. = 12.2, range 1–50), and mean daily cigarette 
consumption is 19.0 (S.D. = 6.3, range 10–40). 
 
3.2. Effects of nicotine versus placebo lozenges 
 
Twenty-seven participants gave breath CO readings in excess of 10 ppm on one or both of the two 
lozenge testing occasions, suggesting that they had not complied with the experimental instruction to 
abstain overnight beforehand or, for very heavy smokers, that there was still residual nicotine in their 
system. These participants were therefore excluded from further comparisons, leaving 82 in the 
analyses of experimental measures. Data were analysed using repeated measures analyses of variance 
with the within-subjects factor of lozenge type (LOZTYPE: placebo vs. nicotine) and with order of 
lozenge sessions as a between-subjects factor (LOZORDER: placebo first vs. nicotine first). Because 
LOZORDER in no case interacted significantly with LOZTYPE, it is not mentioned further. 
 
3.2.1. CARROT reward responsivity 
 
ANOVA included the additional within-subjects factor of REWARD (rewarded vs. mean 
of the two nonrewarded trials). 
 
Sorting rate was significantly faster in the rewarded trial [0main effect of REWARD: F(1,80) = 8.5, P < 
.005]. Although there was no main effect of LOZTYPE [F(1,80) < 1.0, ns], there was a trend towards 
the predicted REWARD х LOZTYPE interaction [F(1,80) = 3.5, P < .07] with similar sorting rates in 
the nonrewarded trials for nicotine and placebo conditions but a greater acceleration in response to 
reward in the nicotine condition (see Fig. 1). 
 
                                                 
1 As the study is ongoing, not all data collected have yet been entered. 
 
 
Fig. 1. Card-sorting rates (cards per second) on the CARROT in nicotine and placebo lozenge 
conditions. 
 
3.2.2. Modified Stroop 
 
ANOVA included the additional within-subjects factor of WORDTYPE (neutral, pleasure, aversive, 
smoking). To compare the effect of nicotine on interference from each of the three salient word types 
(pleasure, aversive, and smoking), we specified a priori contrasts of each of these three word types 
individually against the neutral words. 
 
There was no main effect of LOZTYPE for either colour-naming times or errors [F(1,79) = 1.6 and < 1, 
both ns]. For colour-naming times, although the omnibus LOZTYPE х WORDTYPE interaction also 
fell short of significance [F(3,77) = 1.4, ns], the a priori contrasts revealed that relative to the speed of 
colour naming neutral words, there was a trend for nicotine to be associated with heightened 
interference from pleasure words [F(1,79) = 3.5, P=.07] but not from either aversive or smoking-related 
words [F(1.38) < 1, ns, in both cases)]. 
 
For errors, however, the omnibus LOZTYPE х WORDTYPE interaction was significant [F(1,79) = 3.0, 
P < .05], and this reflected greater interference from pleasure relative to neutral words in the nicotine 
than in the placebo condition [F(1,79) = 9.2, P < .005; see Fig. 2]. There was no effect of nicotine on 
interference from either aversive or smoking-related words [F(1,79) = 1.0 and 1.6, ns, in both cases]. 
Given that the error data were not normally distributed, with over half the participants making only one 
or no errors for any given word type, the effect of nicotine on neutral words (i.e., errors under placebo 
minus errors under nicotine) was additionally compared with its effect on pleasure words using the 
nonparametric Wilcoxon’s signed rank test. This confirmed the difference as significant (Z = —2.8, P < 
.01). 
 
3.2.3. SHAPS scores 
 
Data were missing for four participants. For the remaining 78 participants, anhedonia was significantly 
greater in the placebo condition (M= 9.4, S.D. = 5.6) than in the nicotine condition [M= 7.9, S.D. = 5.6; 





Fig. 2. Colour-naming errors for different word types on the modified Stroop, in nicotine and placebo 
lozenge conditions. 
 
3.2.4. Saccadic and antisaccadic eye movements 
 
ANOVA included the additional within-subjects factor of SACCTYPE (prosaccades vs antisaccades). 
Some data were missing for 14 participants owing to technical difficulties during one or both testing 
sessions; thus the analysis is based on 68 participants. 
 
For accuracy, there were main effects of LOZTYPE [F(1,66) = 10.3, P < .002] and SACCTYPE 
[F(1,66) = 206.0, P < .001], with more errors being made for antisaccades than prosaccades and more 
errors overall under placebo than nicotine. The LOZTYPE х SACCTYPE interaction was highly 
significant [F(1,66) = 10.7, P < .002]: Participants scored at close to ceiling on the prosaccadic task 
regardless of lozenge condition but made markedly more errors on the antisaccadic task in the placebo 
than in the nicotine condition. These data are shown graphically in Fig. 3. 
 
Reaction times (for accurate responses) were no faster under nicotine than placebo [F(1,66) = 1.9, ns], 
although, generally, reactions were much slower on antisaccadic than prosaccadic trials [F(1,66) = 
435.0, P < .0001]. There was no LOZTYPE х SACCTYPE interaction [F(1,66) < 1, ns]. 
 
3.3. Prediction of duration of abstinence at 7-day follow-up 
 
Of the 59 participants who were subsequently allocated to the quit group and assessed after 7 days, 40 
(66%) reported still being abstinent. As yet full salivary cotinine data are not available to verify these 
self-reports. 
 
For the four experimental measures reported above, the effect of nicotine was computed for each 
individual participant. In most cases this was achieved by subtracting their score in the placebo 
condition from their score in the nicotine condition, but where a high score indicated poor functioning 
 
 
Fig. 3. Accuracy (number of correct out of 60) on the prosaccadic and antisaccadic trials of the oculomotor task, in 
nicotine and placebo lozenge conditions. 
 
(e.g., reaction times, SHAPS anhedonia), nicotine scores were subtracted from placebo scores. Thus, in 
each case a high positive score indicates a beneficial effect of nicotine. The hypothesis that participants 
who had experienced greater benefits of nicotine (or detriments of abstinence) would be at greater risk 
of early relapse was tested by comparing relapsers versus nonrelapsers via a series of independent 
samples t tests. 
 
The two groups did not differ in the extent to which nicotine ameliorated anhedonia (relapsers, 
M=1.4±3.6; nonrelapsers, M=1.9±4.7; t < 1, ns) or increased CARROT reward responsivity (relapsers, 
M= 0.03±0.07; nonrelapsers, M= 0.02±0.12; t < 1, ns). 
 
On the Stroop task, the comparisons of interest related to the interference effect from pleasure words 
(i.e., the difference between pleasure and neutral words). In relation firstly to error rates, the previously 
observed effect of nicotine in increasing interference from pleasure related words on colour-naming 
accuracy did not differ between the relapsers and nonrelapsers (M= 0.1±1.8, and M= 0.83±2.2, 
respectively; t = 1.2, ns). However, for colournaming times (where overall nicotine was found to 
selectively increase response times to pleasure words relative to neutral words) there was a trend for 
the relapsers to show a more pronounced effect of nicotine in increasing attentional bias towards 
pleasure words than the nonrelapsers (M= 3.3±6.3 and M=_0.8±8.2, respectively; t = 1.9, P=.06). 
 
Finally, for the oculomotor response inhibition task, the indices of key interest were the differences in 
error rates and response latencies between the prosaccadic and antisaccadic conditions. In each case, 
response inhibition impairment was computed by subtracting the prosaccadic score from the 
antisaccadic score so that a high positive score indicated greater difficulty in the antisaccadic condition. 
The effect of nicotine in improving response inhibition was therefore calculated by subtracting the 
nicotine score from the placebo score. Participants who went on subsequently to relapse showed 
markedly greater benefit from nicotine in improving their response inhibition (M= 10.7±14.9) than did 
those who were still abstinent a week later (nonrelapsers: M= 1.1±10.7; t = 2.6, P < .01). However, 
there was no difference between the two groups in the extent to which nicotine decreased the relative 
response latency for accurate antisaccadic responses (relapsers, M= 0.02 ± 0.09; nonrelapsers, -.01± 








These preliminary analyses on about half of our projected final sample of 200 smokers are largely 
consistent with our previous findings that acutely abstinent smokers show impairments of incentive 
motivation and response inhibition that can be reversed by smoking. The fact that the present study 
used a placebo-controlled design in which nicotine was administered in lozenge form strongly suggests 
that the previously observed effectiveness of cigarettes in reversing these impairments is attributable to 
their nicotine content rather than to other ingredients or expectancy effects. 
 
There were, however, one or two minor discrepancies from previous findings. Firstly, the effect of 
nicotine on reward responsivity on the CARROT fell just short of significance, despite the sample 
being larger than in our previous work using cigarettes. It remains to be seen whether the effect will 
achieve significance when recruitment is complete; however, the weaker effect may reflect variations 
in pharmacokinetics associated with different mechanisms of delivery: thus, smoking achieves a more 
rapid surge in blood nicotine levels than does the slow, steady release produced by sucking a lozenge. 
The second discrepancy is in relation to the Stroop test of attentional bias, where the present sample 
showed increased sensitivity to appetitive stimuli (as reported previously) but not to stimuli with 
aversive connotations; in our earlier study (Powell, Tait et al., 2002), nonsmokers and smokers who 
had just had a cigarette showed equivalent biases towards both classes of motivationally salient cue. 
However, corresponding with the present findings, in a more recent unpublished study using the same 
task with social drinkers (McFie and Powell, in preparation) a priming dose of alcohol was found to 
increase bias specifically towards the appetitive and not the aversive words. 
 
Although we currently have follow-up data 1 week after commencement of a quit attempt on only 
about 60 participants, and as yet do not have available a complete set of objective physiological 
indicators of abstinence to verify subjective reports, there are nevertheless already some interesting 
indications that deficits on some tasks during acute abstinence may indeed contribute to early relapse. 
In particular, relapse within 1 week of cessation was significantly predicted by the extent to which 
nicotine ameliorated abstinence-related impairments of both response inhibition and attentional bias 
towards words with incentive salience on the Stroop task. At this stage we have not embarked on 
regression analyses to explore the extent to which different predictors contribute independently to 
outcome, although this will clearly be a matter of priority when data are available on the full, 
considerably larger, sample. 
 
As noted previously, there are a number of additional issues that the present study has been designed to 
address and that we have as yet not begun to explore. These include, importantly, the question of 
whether deficits that are manifest after only a few hours abstinence show recovery with increasing 
duration of abstinence. It may be that some measures are more susceptible to practice effects than 
others, thereby limiting their predictive utility and also their sensitivity to recovery over time; the 
CARROT, for instance, may be one such test since inspection of the current data set suggests that the 
difference between participants tested under nicotine and placebo conditions—although still evident—
was much less pronounced on the second lozenge session than in the first. 
 
Another interesting issue concerns possible interrelationships between susceptibility to relapse, the 
experimental measures used here, and personality and genetic factors that have been theoretically or 
empirically linked with functioning of brain reward or dopamine pathways: It may be, for instance, that 
some individuals with constitutionally hypofunctioning reward systems may be particularly drawn to 
the use of addictive substances because they are particularly effective for them in modulating 
psychological experience (see, e.g., Blum et al., 2000). In this case, we might expect nicotine 
administration to be associated with stronger effects in personality or genetically defined subgroups. 
Data pertaining to some such variables have been collected within this study and will allow exploration 
of individual differences in drug effects. 
 
To conclude, contemporary neurobiological theories of addiction and their associated investigative 
techniques are already delivering much more than a detailed description of the physiological processes 
associated with drug use: They have amplified our understanding of clinically observed features of 
addiction such as craving, motivational distortions, and poor impulse control, and will undoubtedly 
continue to do so. They complement cognitive and psychological accounts of these phenomena, and 
have the potential to contribute to the refinement and individual targeting of psychosocial and 
pharmacological intervention strategies. 
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